Novo-Catalent deal cleared without conditions in Brazil; parties agree to confidentiality measures
Novo Holdings’ proposed acquisition of drugmaker Catalent was approved without restrictions by the Brazilian competition authority, but the parties agreed to make commitments to ensure the confidentiality of projects of clients...To view the full article, register now.
Already a subscriber? Click here to view full article